Japan approved partial change to a NDA for Omicron-targeting bivalent booster COVID-19 vaccine
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
On Oct. 27, 2022, Inovio Pharma announced that it has discontinued its internally funded efforts to develop INO-4800…
On Oct. 27, 2022, the National Institutes of Health (NIH) announced that overall cancer death rates continued to…
On Oct. 25, 2022, the University of Washington reported that daily global COVID-19 infections were projected to rise…
On Oct. 25, 2022, Pacific Northwest National Laboratory (PNNL) announced that scientists have shown that they can detect…
On Oct. 19, 2022, the U.S. Food and Drug Administration (FDA) recommended the use of the Novavax COVID-19…
On Oct. 19, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
On Oct. 19, 2022, Pfizer and BioNTech announced that the European Medicines Agencyメs (EMA) Committee for Medicinal Products…
On Oct. 17, 2022, Moderna and Gavi, the Vaccine Alliance, announced they had mutually agreed to cancel remaining…
On Oct. 13, 2022, Novavax announced positive results from the Phase 1/2 clinical trial of its COVID-19-Influenza Combination…
On Oct. 13, 2022, Pfizer and BioNTech announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating…
On Oct. 13, 2022, researchers from the University of Oxford reported findings from a study exploring how certain…
On Oct. 12, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
On Oct. 12, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration granted Emergency Use…
On Oct. 11, 2022, researchers from the University of Oxford have reported new findings from a Phase 1…
On Oct. 10, 2022, Novavax announced that partner, SK bioscience, had submitted a Post Approval Change Application to…
On Oct. 10, 2022, Novavax announced that Switzerland’s Federal Office of Public Health had recommended Nuvaxovid (NVX-CoV2373) as…
On Oct. 6, 2022, Merck announced data from two real-world evidence studies evaluating LAGEVRIOル (molnupiravir), an investigational oral…
On Oct. 4, 2022, Washington University in St. Louis announced it had licensed the rights to develop, manufacture…
On Sept. 28, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
On Sept. 27, 2022, the National Institutes of Health (NIH) announced that a large international study had confirmed…
On Sept. 27, 2022, Novavax announced that an initial one million doses of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine were…
On Sept. 28, 2022, Pfizer and BioNTech announced they have completed a submission to the U.S. Food and…
On Supt. 22, 2022, Pfizer announced an agreement to supply up to six million treatment courses of its…
On Sept. 16, 2022, Novavax announced that the Taiwan Food and Drug Administration had granted expanded emergency use…
On Sept. 16, 2022, Novavax announced that the Israel Ministry of Health had granted an import and use…
On Sept. 15, 2022, Gilead Sciences announced updates to the World Health Organizationメs Therapeutics and COVID-19: living guideline,…
On Sept. 13, 2022, Novavax and Serum Institute of India, the world’s largest vaccine manufacturer by volume, announced…
On Sept. 2, 2022, Novavax announced that Swissmedic, the Swiss Agency for Therapeutic Products, had expanded its temporary…
On Sept. 2, 2022, Novavax announced that the World Health Organization (WHO) had approved a variation to allow…